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INTRODUCTION
Hidradenitis suppurativa (HS), also known as acne inver-
sa or Verneuil´s disease, is a chronic, inflammatory and re-
current skin disease of the hair follicle that usually presents 
after puberty with painful, deep-seated, inflamed lesions in 
the apocrine gland-bearing areas of the body.1 Originally 
described by Verneuil, in 1854, the pathogenesis was at-
tributed to a disorder of the apocrine sweat glands, hence 
the name "hidradenitis".2 The perception that the main event 
in the origin of HS involves the hair follicle as in acne-like 
disorders lead to the suggestion of the term acne inversa.3
More studies on epidemiology and pathophysiology are 
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currently underway, and seem mandatory to better unders-
tand this disease and improve therapeutic approach.
1. DEFINITION AND DIAGNOSIS
The diagnosis of HS is clinical. According to the modi-
fied Dessau definition, 3 criteria must be present: typical 
lesions, including nodules, sinus tracts, abscesses, scarring 
and double-ended pseudocomedones; location in at least 
one area for which HS has a predilection namely the axilla, 
genitofemoral area, perineum, gluteal area and infra- and 
intermammary folds (although lesions may appear ectopi-
cally); and history of chronicity and recurrence (more than 2 
recurrences over a period of 6 months).1,4
2. DIFFERENTIAL DIAGNOSIS
Several infectious and non-infectious dermatoses need 
to be differentiated from HS (Table 1).
3. CLASSIFICATION AND SEVERITY ASSESSMENT 
3.1 - Hurley staging
In 1989, Hurley5 first proposed a severity classification 
consisting in 3 stages (Table 2). Stage I disease is the most 
common (68% of patients), while stage II occurs in 28% of 
patients, and 4% of HS patients have stage III.1 Hurley clas-
sification is useful for quick HS severity assessment. Howe-
ver, it is not a precise monitoring tool, namely for accessing 
therapeutic efficacy.1,4 Fig.s 1, 2 and 3 illustrate typical cases 
of HS patients with Hurley 1 to 3 disease, respectively. Re-
cently, a revised version of Hurley staging was proposed.6 
It consists on a 3 steps algorithm, including assessing the 
Figure 1 - Typical case of HS patient with Hurley 1 disease. 
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Table 2 - Hurley staging*.
Stage I - Abscess formation, single or multiple, without sinus 
tracts and cicatrization 
Stage II - Recurrent abscesses with tract formation and 
cicatrization, single or multiple, widely separated lesions 
Stage III - Diffuse or near-diffuse involvement or multiple 
interconnected tracts and abscesses across the entire area.
*Adapted from Hurley.6
Table 1 - Differential diagnosis of hidradenitis suppurativa*.
Carbuncle Cutaneous Crohn disease Noduloulcerative syphilis
Epidermoid/dermoid cyst Simple abscesses Blastomycosis 
Erysipelas Neoplasms Scrofuloderma (Tuberculosis)
Furuncle Lymphogranuloma venereum    Granuloma Inguinale/Donovanosis
Pilonidal cyst Cutaneous actinomycosis
*Adapted from Zouboulis et al.1
Figure 2 - Typical case of HS patient with Hurley 2 disease. 
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presence of sinus tracts, degree of inflammation and the ex-
tension, which enables the clinician to assess severity across 
the different phenotypes of HS and helps guiding treatment.6
3.2 - Sartorius Score 
This scoring system, described in Table 3, was the first 
disease specific instrument for dynamically measuring clini-
cal severity.1 The parameters in the modified Sartorius score 
include counting of individual nodules and fistulas, mea-
suring the longest distance between 2 lesions, and adding 
extra points to Hurley III stages.7 It is rarely used in clinical 
practice as it is time consuming and complex.
3.3 - Physician Global Assessment (PGA)
Currently, PGA, a 6 stages classification, is the most fre-
quently used tool in clinical trials to measure treatment effi-
cacy (Table 4).1,8
3.4 - Hidradenitis Suppurativa Clinical Response (HiSCR)
The HiSCR score is defined as a ≥ 50% reduction in the 
number of transient inflammatory lesions (sum of abscesses 
and inflammatory nodules) and no increase in abscesses or 
draining fistulas (chronic inflamed lesions) when compared 
with baseline.9 However, it is designed to assess treatment 
response, not disease severity cross-sectionally.4
3.5 - International Hidradenitis Suppurativa Severity 
Score System (IHS4)
The novel IHS4, a systematically constructed, validated 
and simple tool to dynamically assess HS severity, can be 
adapted both to clinical research and daily practice.10 IHS4 
evaluation requires counting of nodules, abscesses and 
draining fistulas/sinus tracts (Table 5).
3.6 - Medical imaging techniques
Staging and monitoring have been traditionally based 
on clinical findings.11 However, HS is characterized by pre-
dominantly dermal pathology and therefore, difficult to 
assess clinically.12 Physical examination has important limi-
tations with poor sensitivity for differentiating lesion subtypes 
and defining disease activity.11,12 Recently, noninvasive ima-
ging techniques as ultrasound (US) and magnetic resonance 
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Figure 3 - Typical case of HS patient with Hurley 3 disease. 
Table 3 - Sartorius Score*.
I- Anatomical region involved (axilla, groin, gluteal or other 
region or inframammary region left and/or right: 3 points 
per region involved).
II- Number and scores of lesions (abscesses, nodules, 
fistulas, scars: points per lesion of all regions involved: 
nodules 2; fistulas 4; scars 1; others 1).
III- The longest distance between two relevant lesions, 
i.e. nodules and fistulas, in each region, or size if only one 
lesion (< 5 cm, 2; < 10 cm, 4; > 10 cm, 8).
IV- Are all lesions clearly separated by normal skin? In 
each region (yes 0 / no 6).
*Adapted from Sartorius et al.7
Table 4 - Physician Global Assessment*.
Clear - No inflammatory or non-inflammatory nodules
Minimal - Only the presence of non-inflammatory nodules
Mild - <5 inflammatory nodules without abscesses and 
draining fistulas or 1 abscess or draining fistula without 
additional inflammatory nodules
Moderate - <5 inflammatory nodules, or 1 abscess or 
draining  fistula and ≥1 inflammatory nodules, or 2-5 
abscesses or draining fistulas and <10 inflammatory 
nodules
Severe - 2-5 abscesses or draining fistulas and ≥10 
inflammatory nodules
Very severe - >5 abscesses or draining fistulas
*Adapted from Kimball et al.8
Table 5 - International Hidradenitis Suppurativa 
Severity Score System (IHS4)*.
Number of nodules multiplied by 1
Number of abscesses multiplied by 2
Number of draining tunnels (fistulae/sinuses) multiplied by 4
A score of ≤3 signifies mild HS; a score of 4-10 signifies 
moderate HS and a score of ≥11 signifies severe HS.
*Adapted from Zouboulis et al.10
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imaging (MRI) were shown useful and allowed a better un-
derstanding of HS as a pathology with subclinical anatomi-
cal manifestations undetected by clinical examination.11-13 
These imaging techniques can also be crucial to guide sur-
geons in the complete removal of chronic HS lesions, impor-
tant in HS management.11-13 Finally, these techniques may 
improve the diagnosis of Marjolin ulcers in HS, which is a 
rare but serious complication.11,13,14
Recently proposed US diagnostic and staging criteria are 
also important for a standardized HS nomenclature.11,12,15
4. PAIN ASSESSMENT IN HS
Pain in HS has many components namely nociceptive, 
neuropathic, inflammatory, ischemic and pain related to co-
morbidities.16
Reflecting its importance, many instruments have been 
created to assess therapeutic efficacy in drug trials. The nu-
merical rating scale (NRS), where 0 denotes no pain and 
10 severe pain, is a reliable tool for a baseline pain as-
sessment.16 Another instrument, the Visual Analogue Scale 
(VAS), although subjective, allows evaluation of pain severity 
in a continuous way (Fig. 4).
5. PSYCHOSOCIAL IMPACT 
As a chronic painful disease, HS is, not surprisingly, as-
sociated with poor quality of life (QoL).1
HS has a far-reaching effect on all areas of life and QoL 
has been found to be more significantly impaired in HS 
than in diseases like psoriasis, neoplasms, strokes or even 
heart transplant candidates.17,18 Furthermore, problems in 
the familial and social environment, suicidal ideas, fear of 
stigmatization, and economic difficulties, contribute to the 
substantial burden of disease.1 Some studies underline the 
significant work disability rate together with high unemploy-
ment rate among HS sufferers.1,19,20 An additional contri-
butor to impaired QoL is sexual dysfunction, particularly 
because of the influence of HS on intimate relationships and 
sexual activity.18,21
6. EPIDEMIOLOGY
HS is an under recognized entity with a significant delay 
from the onset of symptoms to the diagnosis,22,23 with a 
median delay of 12 years in one study.24 Prevalence is a 
matter of debate, with estimated rates as low as 0.00033% 
up to 4%.18 A recent USA population-based study found an 
overall annual incidence of 6 per 100 000.25 However, in 
Europe two studies reported a much higher prevalence of 
1%26,27 and Jemec et al28 even found a prevalence of 4% in 
a young adult female population in Denmark. Discrepan-
cies between European and American studies may be due to 
different methodologies.1 Recently, a Portuguese nationwide 
hospital-based study showed a 15-year HS prevalence of 
0.075%, but it included only patients who sought healthcare 
services, indicating that HS may be strongly underdiagnosed 
and mostly undertreated.29
HS is mainly a disease of young adults with no speci-
fic racial predilection.30 The age of onset ranges from the 
second to the fifth decade, with a mean in the early 20s.18 
However, HS has also been reported in children and after 
menopause.18,31,32 In fact, 2% of cases occur before the age 
of 11.32
HS prevalence appears to be significantly higher in 
women, with female: male ratios ranging from 2.5:1 to 
4:1.22 This ratio decreases in older patients as there is consi-
derable evidence of a decline in prevalence in women after 
the age of 55 and not so evident in males, which may reflect 
hormonal changes due to menopause.18,26
7. PATHOGENESIS
The exact mechanisms underlying HS are not entirely es-
tablished.33 Due to its characteristic localization in regions 
with a high density of apocrine glands, it was initially as-
sumed that the inflammation of these glands, the so called 
apocrinitis, was the primary event.34 However, it is now ge-
nerally accepted that apocrine glands are secondarily in-
volved and the primary histopathologic event seems to be 
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Figure 4 - Visual Analogue Pain Scale.  Adapted from Yale University.141
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follicular hyperkeratosis with plugging, followed by dilation 
and rupture of the hair follicle with subsequent inflammation 
and formation of abscesses and sinus tracts.34 The cause is 
likely multifactorial, involving a genetic tendency, smoking, 
mechanical stress, obesity, immune aberrant response and 
hormonal abnormalities.33
7.1- Inflammation
HS is closely linked to other immune-mediated diseases 
and responds to immunosuppressive agents, suggesting, at 
least in part, an immune basis for this disease.18
Tumor necrosis factor alpha (TNF-α), although present in 
inflammatory HS skin, may not be the key player in its pa-
thogenesis.33 A recent study demonstrated enhanced mRNA 
expression of TNF-α in lesional and perilesional HS skin, 
but it was less pronounced than the increase of IL-17 and 
IL-1beta.33,35 Furthermore, the proinflammatory cytokines 
IL-12 and IL-23 are abundantly expressed by macrophages 
infiltrating papillary and reticular dermis in HS.36
A subclinical inflammatory state occurs in the skin prior 
to the onset of a visibly active HS.33 The process may begin 
as an aberrant keratinocyte response to bacteria of the nor-
mal microbiome with inappropriate production of cytoki-
nes and antimicrobial peptides.37 Attracted immunocytes 
further secrete pro-inflammatory cytokines and chemoki-
nes.38 Enhanced by obesity, smoking and defective Notch 
signaling, in the inflammatory microenvironment the folli-
cular epithelium responds with hyperplasia, infundibular 
keratosis, follicular occlusion and cyst formation.37,38 Cysts 
expand, rupture and expel contents into the dermis inclu-
ding bacteria and keratin, triggering a neutrophilic foreign 
body reaction.33,37 Bacterial invasion and biofilm formation 
causes follicular destruction and abscess formation.33,37 It is 
proposed that free keratin activates the NLRP3 inflammaso-
me with IL-1 cleavage and IL-1beta secretion.33,37 Along with 
IL-23 and IL-6, IL-1b promotes the secretion of innate IL-17 
and activation of Th17 cells, which in turn release IL-17, 
IL-22, and TNF-α.33,37,39 Residual free keratin perpetuates 
responses and follicular epithelial strands remaining after 
cyst rupture form fistulae that harbor bacteria and promote 
suppuration.33
Although the precise cytokine profile and immune path-
ways are not fully elucidated, various studies demonstrated 
IL-17, IL-1b and IL-23 increase and implicate the IL-1b-
IL-23/ TH17/IL-17 pathway in HS pathogenesis.33,38,40
7.2 - Obesity and other endocrine abnormalities
Most HS patients are overweight or obese with a sizable 
body of literature demonstrating obesity as a paramount risk 
factor for HS1,41 and probably also a risk for HS severity.1 
Some factors may explain the pathophysiologic mechanis-
ms behind this association. Adipose cells are capable of se-
creting proinflammatory cytokines, which may contribute to 
follicular hyperkeratosis and development of HS lesions.41 
Furthermore, large body folds in obesity increase mecha-
nical stress and promote a warm, humid microclimate 
favoring bacterial overgrowth which may also have a pa-
thogenic role.41 A cross sectional study, compared 205 HS 
patients with a high (above 35) body mass index (BMI) with 
246 HS patients with a low BMI (below 25).42 Those with a 
high BMI significantly suffered more severe disease (Hurley, 
PGA, number of areas affected and patient reported seve-
rity) and patients with low BMI significantly reported greater 
severity when they increased their BMI.42 The authors con-
cluded patients with a low and high BMI could represent two 
clinically different subtypes of HS suggesting a non-linear 
relationship between BMI and impact of HS.42 
The role of androgens and sexual hormones remains 
controversial,34 but many  facts support a possible relation: 
- the typical onset in a narrow age spectrum after puberty; 
- rare postmenopausal onset34; 
- usual improvement during pregnancy and post-partum 
flare-up34; 
- reports of association with irregular menses, hirsutism and 
higher concentration of total testosterone,43 although not 
constant28,44; 
- reports of significant remission after antiandrogen therapy, 
although most of HS patients have normal androgen profi-
les45,46; 
- HS in children under 12 is more likely associated with hor-
monal imbalance, namely adrenal hyperplasia, premature 
adrenarche, obesity, and metabolic syndrome.47 
In fact, a diagnosis of HS in children may be a marker of 
precocious puberty.47   
7.3 - Smoking
Rates of smoking in HS patients have been noted as high 
as 42% and 92%.18,48 An association between HS and cur-
rent smoking was confirmed in a French cohort of 10 000 
subjects but not in former smokers.26 Conversely, smoking 
cessation may improve HS.49
Smoke components can activate keratinocytes, fibro-
blasts, and immunocytes, inducing proinflammatory cytoki-
nes.1,38 Additionally, tobacco smoke leads to modification 
of the skin microflora contributing to biofilm formation and 
further suppresses the Notch signaling that is already defi-
cient in HS.38,50,51
7.4 - Genetics 
Up to 40% of patients have a familial history of HS and 
an autosomal dominant pattern of inheritance has been 
observed.1,49,52 Although several genetic loci have been 
recognized, a single causative gene remains unidentified. 
Recent genetic studies highlighted the role of the enzyme 
γ-secretase with heterozygous mutations reported in the 
γ-secretase genes PSENEN, PSEN1, and NCSTN.52 These 
mutations may contribute to 5% of HS cases leading to at-
tenuated Notch signaling, an important modulator of T-cell 
mediated immune responses, inhibition of the hair growth 
cycle and conversion of hair follicles into keratin enriched 
epidermal cysts.33,38 Additionally, certain TNF gene polymor-
phisms seem to be associated with HS, which is consistent 
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with a greater reduction of disease severity after anti-TNF 
treatment.53
7.5 - Mechanical stress 
Predisposed HS skin areas are sites of regular mecha-
nical stress.54 Friction may promote follicular occlusion and 
rupture of dilated follicles in genetically susceptible pa-
tients.42 One study with histopathology and case reports 
found increased fragility of the dermoepidermal junction in 
HS patients, which suggests that friction may contribute to 
HS development.54
7.6 - Microbiology 
The efficacy of antibiotics in HS supports a microbial role 
in its pathogenesis.55 However, these antibiotics also have 
anti-inflammatory activity.55 Therefore, the underlying me-
chanisms may be more complex.55,56
Bacterial collection from superficial lesions has frequently 
shown negative results or a mixed growth of commensal mi-
crobes.33,57,58 Studies using CO2 laser vaporization of lesional 
skin level by level or aspirating pus from the deeper parts of 
HS lesions to prevent contamination by the normal skin mi-
croflora, found Gram-positive cocci and rods including Sta-
phylococus aureus, coagulase-negative staphylococci (CoNS) 
as S. epidermidis, Corynebacterium species and anaerobes 
of the commensal flora.1,55 Biofilm formation can also have 
a role in HS.56 A retrospective study of 27 patients using his-
topathology found biofilm-like structures in one-fifth of the 
samples.59 It is also possible that chronic HS lesions may re-
semble an environment such as one produced by a foreign 
body promoting and maintaining bacterial growth.56
No yeasts or other infectious agents were found to play 
an important role in the pathogenesis. A polymicrobial flora, 
and, in particular, the dominating S. aureus/CoNS in HS le-
sions, may raise speculations on the pathogenic significance 
of these recurring bacteriologic findings.56 Whether bacte-
rial colonization is a primary or a secondary event of an 
initially sterile process is still a subject of much debate.56,59
8. COMORBIDITIES
As a chronic inflammatory dermatosis, HS is associated 
with a variety of concomitant and secondary diseases.
8.1 - Metabolic 
Increasing evidence suggests association with the meta-
bolic syndrome, which may affect more than 50% of HS pa-
tients, with subsequently increased cardiovascular risk.1,18,60 
Possible mechanisms behind this association include the 
long-term effects of the chronic inflammatory state, the se-
dentary lifestyle of most HS patients, inflammation-induced 
neuropsychological factors affecting appetite and cortisone 
levels, and concomitant pharmacotherapy.18
8.2 - Inflammatory and rheumatologic
A retrospective study61 found that 38% of HS cases also 
had Crohn’s disease (CD) and a recent study found that 
23% of patients with inflammatory bowel disease also had 
HS.62
Several syndromes with pyoderma gangrenosum (PG) 
and HS have been reported, consisting on a triad of PG, 
acne conglobata and HS, differentiated clinically by their 
arthritic component: PAPASH (pyogenic arthritis), PASS (se-
ronegative spondyloarthritis) and PASH (no arthritis).18,63 
Besides, there are many reports of non-syndromic PG and 
HS.1,18
Rheumatologic joint conditions have been reported in 
association with HS: axial arthritis, peripheral arthritis (in-
cluding dactylitis), enthesopathies, synovitis-arthritis-pustu-
losis-hyperostosis-osteitis (SAPHO) syndrome, and specially 
the spondylarthropathies, sometimes in association with 
CD.1,18
In addition, HS belongs to the group of diseases charac-
terized by follicular occlusion known as the follicular occlu-
sion tetrad: HS, acne conglobata, dissecting cellulitis of the 
scalp, and pilonidal cysts.64 Acne vulgaris, keratitis–ichthyo-
sis–deafness syndrome and Dowling–Degos disease have 
also been associated with HS.1,18 Scarce data also proposed 
a link between HS and Down syndrome.65
 
8.3 - Malignancies
HS has been associated with increased risk of cutaneous 
malignancy.14,15 A recent revision found 52 cases of squa-
mous cell carcinoma (SCC) published between 1958 and 
2009.66 This can be an underreported complication as in 
some series the prevalence of SCC in HS was as high as 
4.6%.66 Scheinfeld67 proposed a possible synergistic effect 
between chronic inflammation, impaired cellular immunity, 
and the presence of the human papillomavirus, however this 
is still under debate.67 
The association between visceral cancers and HS is more 
controversial and needs clarification.1
8.4 - Depression
There is significant evidence that HS carries a high in-
cidence of depression, with reported rates of 48.1% and 
42.9% in 2 cross-sectional analyses,25,68 although with lower 
values in other studies.1,69,70
 
8.5 - Other complications
Surprisingly, acute super-infection, including cellulitis 
and erysipelas, and enlarged lymph nodes are very unusual, 
with an incidence lower than expected.1,71
Lymphatic obstruction and lymphedema, fistulae formation 
and elephantiasis may complicate long-standing disease.1
Other HS complications include anemia, amyloid depo-
sition and kidney failure.18,72-75
9. TREATMENT
Treatment varies widely depending on disease severity, 
with many treatments supported by weak scientific eviden-
ce.1 Topical, systemic, and surgical therapies are available 
and are often used in combination (Table 6).
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9.1 - General measures 
Based on pathophysiological mechanisms, the general ex-
pert opinion proposes weight loss, smoking cessation, avoi-
dance of tight-fitting clothing and management of concomitant 
comorbidities,1 however, there is no consistent data to prove 
the benefit of these measures. Although frequently recommen-
ded, studies to support the routine use of topical aseptic wa-
shing and dressings of involved areas are lacking.76,77
9.2 - Topical therapy 
Topical keratolytic agents and topical antibiotics have 
been used in the management of patients with mild HS, 
based on the possible involvement of follicular occlusion 
and the role of bacteria.1 Topical resorcinol 15% is an exfo-
liant with keratolytic, antipruritic, and antiseptic properties. 
In one prospective study enrolling 12 women with mild HS 
there was a significant pain decrease and reduction in mean 
duration of painful abscesses in all patients.78 The European 
guideline on HS recommended the application of a lotion 
containing clindamycin 1% b.i.d. for 3 months in patients 
with localized Hurley Stage I or mild stage II disease, since 
clindamycin is the only antibiotic studied as a topical agent.1 
Intralesional corticosteroids are widely used for the ma-
nagement of acute flares of single or limited number of 
inflammatory nodules and may also be helpful for the treat-
ment of recalcitrant nodules and sinus tracts.76,79 Recently, 
Riis et al,80 conducted a prospective multicenter study inclu-
ding 36 patients (3 lost to follow-up), to assess the outcomes 
of routine intralesional triamcinolone (0.2-2.0 mL, mean 
0.75 mL of a 10 mg/mL solution) on nodules or abscesses. 
Authors found a significant reduction in physician-assessed 
size, edema, redness, and suppuration after a mean of 6.9 
days. A significant difference in patient-reported pain visual 
analog scale scores occurred after 1 day.
The efficacy of botulinum toxin injections for HS has 
been reported in 3 cases with positive results in 2.81,82 
In addition, topical retinoids, azelaic acid or fusidic acid 
also have been used in limited cases.1,79
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Table 6 - Hidradenitis suppurativa treatment*.
HIDRADENITIS SUPPURATIVA TREATMENT ACCORDING TO HURLEY STAGE*
Adjuvant 
treatment 
(all stages)
- Weight loss and tobacco cessation
- Avoidance of tight-fitting clothing
- Pain control
- Antimicrobial wash  
- Appropriate dressings
- Management of concomitant comorbidities
Hurley Stage I 
and II
Topical treatments
- Topical antibiotics and keratolytic agents (e.g. clindamycin lotion 1% bid for 3 
months; resorcinol 15% bid) 
- Intralesional corticosteroids 
Systemic treatments
- Oral antibiotics (e.g. oral tetracycline 500 mg bid for 4 month; dapsone 25-200 mg 
daily) 
- Systemic retinoids (e.g. acitretin 0.25 to 0.88 mg/kg daily; alitretinoin 10 mg daily)
- Antiandrogenic therapies (e.g. oral contraceptive pills; finasteride 5mg daily; 
metformin 500-1500 mg daily) 
Surgical/ physical 
treatments
- Less invasive surgical approaches (e.g. local excision, curettage and 
electrocauterization, deroofing, cryoinsufflation)
- Laser and lights therapy (e.g.Nd:YAG, CO2 laser, IPL, PDT, PUVA) 
Hurley Stage 
II to III
(includes 
Stage I to II 
approaches)
Systemic treatments
- Oral antibiotics (e.g. oral rifampin 600 mg daily + clindamycin 300 mg bid for 10 
weeks)
- Systemic immunosuppressants (e.g. ciclosporin 2-6 mg/kg/day)
- Biological treatments (e.g. adalimumab160 mg week 0, 80 mg week 2, then 40 
mg weekly. Consider also, infliximab 5 mg/kg weeks 0, 2 and 6; ustekinumab 45 
or 90 mg at weeks 0, 4, 16 and 28; and anakinra 100 to 200 mg daily)
Surgical/ physical 
treatments
- More invasive surgical approaches (e.g. wide radical excision) 
* Adapted from Danny Barlev et al23.
CO2: carbon dioxide; Nd:YAG: long-pulsed neodymium:yttrium-aluminum-garnet laser; IPL: intense pulse light; PDT: photodynamic therapy; PUVA: 
bath psoralen plus ultraviolet A.
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9.3 - Systemic therapy 
Systemic treatment is indicated when more severe or wi-
despread lesions are present (Hurley stage II and/or III) or 
during acute flares.1
9.3.1- Systemic antibiotics
Systemic antibiotics are the most often prescribed drugs 
for HS.83-85 Oral tetracyclines (doxycycline 100 mg bid, mi-
nocycline 100 mg bid and tetracycline 500 mg bid) for up to 
4 months are often used for mild to moderate HS, although 
published data regarding their efficacy is limited.23,83
The efficacy of a combination of rifampin 600 mg and 
clindamycin 600 mg administered in a single or in 2 divi-
ded daily doses for 10 consecutive weeks is documented in 
several studies (total number of patients, 141) with an ave-
rage of 81% (range, 71% - 85%) of subjects obtaining some 
response.83,86-89 However, the interpretation of these results 
should be made with caution since the definition of HS se-
verity and response to treatment varied between studies.83
In a retrospective study the combination of rifampin (10 
mg/kg once daily), moxifloxacin (400 mg daily) and metro-
nidazole (500 mg t.i.d.), either alone or preceded by syste-
mic ceftriaxone (1 g daily) was effective in 16 of 28 patients 
with Hurley stage II and III disease.90 Main adverse events of 
the treatments were gastrointestinal disorders (64% of pa-
tients) and vaginal candidiasis (35% of females). Reversible 
tendinopathy and hepatitis occurred in 4 and 1 patient, res-
pectively.
 
9.3.2 - Retinoids 
The remote similarities of HS and acne vulgaris led some 
clinicians to use retinoids for the treatment of HS.34 Isotreti-
noin achieves its efficacy by influencing cell-cycle progression 
and cellular differentiation, and particularly by induction of 
apoptosis in sebaceous gland cells.34 However, reduction of 
sebaceous gland size and inhibition of sebaceous gland ac-
tivity is not a good adjuvant for HS treatment, since the volu-
me of the sebaceous glands seems to be a priori reduced in 
this disease.34 Accordingly, the effect of isotretinoin is often 
disappointing and this drug is not recommended for HS.1,34 
On the other hand, acitretin that contributes to normaliza-
tion of cell differentiation and thinning of the cornified layer 
through direct reduction of keratinocyte proliferation rate, 
has been successfully used34 in doses ranging from 0.25 to 
0.88 mg/kg with reported efficacy rates between 50% and 
80%.1,23,91 Acitretin is indicated in the early HS stages but 
can also be advocated in the chronic stages with recurrent 
abscesses with sinus tracts and scarring.1
Alitretinoin has a pharmacologic mechanism similar to 
acitretin, but a much shorter half-life and, thus, teratogenic 
risk is not so long lasting.92 Verdolini et al,92 found a significant 
improvement (78.5%) after treatment with alitretinoin (10 mg 
daily) for 24 weeks in 14 females of child-bearing age.
All retinoids are known for their teratogenic potential, the-
refore contraindicated during pregnancy or breast-feeding, 
and used with contraception during child-bearing age.1
9.3.3 - Systemic corticosteroids 
In HS patients with significant flares, short courses of 
systemic corticosteroids (0.5-0.7 mg/kg oral prednisolone) 
may be used as rescue therapy, but routine long-term use is 
not currently recommended.1,79
9.3.4 - Cyclosporin and other conventional immuno-
suppressive therapies
Cyclosporin is a calcineurin inhibitor with potent immu-
nosuppressive activity which specifically targets T lympho-
cytes.1 Few case reports have documented a good response 
to cyclosporine in patients with severe HS, with treatment 
dosage of 2-6mg/kg used for 6 weeks-7 months.93-95 It 
should be reserved for cases after failure of first, second 
and third line therapies.1
Methotrexate was reported to be ineffective in a series of 
3 patients with severe HS.96 Clinical reports to support the 
use of other immunosuppressive therapies, such as azathio-
prine and mycophenolate mofetil, are lacking.83
9.3.5 - Biologic agents
Biologic agents have been increasingly used in the ma-
nagement of moderate to severe HS. Several molecular-tar-
geted anti-inflammatory drugs, including agents blocking 
the effect of TNF-α, IL-1, IL-12/23, IL-17a and an anti-
-CD20 monoclonal antibody have been used.
Adalimumab is a monoclonal antibody that blocks the 
biological effect of TNF-α.1 Two phase III multicenter trials 
of adalimumab were recently completed, PIONEER I and 
II, enrolling 633 patients.97 Clinical response rates at week 
12 were significantly higher for the groups receiving adali-
mumab 40 mg weekly than for the placebo groups: 41.8% 
versus 26.0% in PIONEER I and 58.9% versus 27.6% in PIO-
NEER II.97 The differences between the two trials could be 
related to the fact that in PIONEER I, patients receiving oral 
antibiotics had to stop treatment for at least 28 days be-
fore baseline whereas in PIONEER II they were allowed to 
continue treatment with antibiotics (tetracycline class) in sta-
ble doses. Adalimumab 160 mg week 0, 80 mg week 2, 
then 40 mg weekly since week 4 is currently approved for 
the treatment of moderate to severe HS. Adalimumab every 
other week seems less effective than weekly.8
Infliximab is a chimeric monoclonal antibody against 
TNF-α. A systematic review of 147 patients treated with infli-
ximab (mostly 5 mg/kg at weeks 0, 2 and 6) found a signifi-
cant improvement in 50% of patients and 39% more showed 
moderate improvement.98 The majority of patients received 
maintenance therapy every 6–8 weeks.98 
Etanercept is considered inefficacious for HS.1,23
Ustekinumab, an anti-IL-12/IL-23 antibody, has also 
been used (45 or 90 mg at weeks 0, 4, 16 and 28) with 
good results.99 In a prospective study, out of 17 treated pa-
tients, 35%, 47% and 12% had a marked, moderate and no 
improvement at week 40, respectively.99
Recently a clinical trial studied the efficacy of anakin-
ra, an antibody directed against IL-1, in severe HS.100 A 
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positive HiSCR at 12 weeks was achieved in 3 of 10 patients 
on placebo and in 7 of 9 on anakinra.100 Additionally, at 
least 10 more patients have been reported, with 7 showing 
a response to 100 to 200 mg anakinra on daily subcuta-
neous doses.101 Canakinumab, another anti-IL-1, also de-
monstrated good response.102
Successful treatment of severe recalcitrant hidradenitis 
suppurativa with the interleukin-17a antibody secukinumab 
was recently reported.103
A successful response was also reported with the mono-
clonal antibody anti-CD20 rituximab (two courses of 200 
mg) in a patient with idiopathic carpotarsal osteolysis and 
chronic active antibody-mediated rejection.104
Investigations are currently ongoing or recruiting for 
diverse biologic agents, such as CJM112 (a fully human 
anti–IL-17A mAb [NCT02421172]) and MABp1 (human 
anti–IL-1a antibody in patients with HS refractory to adali-
mumab [NCT02643654]).105
Paradoxically, HS induced by biologic agents (including 
adalimumab, infliximab, etanercept and rituximab) has also 
occasionally been reported.106
9.3.6 - Antiandrogenic therapy
Although it is a controversial topic, several data show that 
antiandrogens, such as cyproterone acetate, and estrogens 
improve HS, while progestogens induce or worsen HS.107
The competitive and selective inhibitor of the type II isoen-
zyme of 5α-reductase, finasteride (5mg/day) used as mono-
therapy or adjunctive therapy has shown encouraging and 
remarkable results in small case series, including complete 
remission.42-108 Randhawa et al109 used finasteride as adjunc-
tive therapy with significant improvement in a 7 years-old 
child and two 15 years-old adolescents, all female, 2 of them 
with concomitant endocrine disorders. Recently, Mota et al,110 
reported five cases of children with HS Hurley I (4 girls and 1 
boy, diagnosed between the ages of 6 and 11 years) treated 
with oral finasteride as monotherapy (increasing dose up to 
5 mg/day) with overall improvement and no adverse effects, 
but 2 patients relapsed after stopping treatment.
Metformin exerts an antiandrogenic effect by reducing 
ovarian overproduction of androgens.79 In a clinical trial, 18 
of 25 (72%) patients who received metformin (500 to 1500 
mg daily) had a mean 12.7 reduction in their Sartorius score 
at 24 weeks while 7 patients had no response.111
Antiandrogenic therapy can be considered in patients 
with HS who also have diabetes or women with menstrual 
abnormalities, signs of hyperandrogenism or polycystic 
ovary disease.1,83
9.3.7 - Other systemic treatments
Dapsone: In a retrospective review of 24 patients,112 a 
slight or significant clinical improvement was observed in 9 
(38%), but no one with severe disease (Hurley Stage III) res-
ponded. Therefore, dapsone, 25-200 mg a day, should be 
reserved for patients with mild to moderate disease (Hurley 
stage I or II).1
Zinc Gluconate: A study of 22 patients with mild to mo-
derate HS receiving zinc gluconate (90 mg/day) for at least 
6 months demonstrated a complete remission in 36% of the 
patients.113
Intramuscular gamma-globulin (IgG): Four out of five 
HS patients demonstrated 50-70% improvement in 1 retros-
pective case series.114
Tacrolimus: In 2 patients with a kidney transplant and 
comorbid HS, all lesions disappeared after a switch from 
cyclosporine to tacrolimus while maintaining mycopheno-
late.115,116
Fumarates: In one prospective case series, 3 out of 7 
patients with moderate to severe HS had a meaningful im-
provement.117
Staphage lysate: In a study of 31 patient’s treatment 
with staphage lysate (obtained by bacteriophage lysis of Sta-
phylococcus aureus) was of greater benefit than placebo.118
Colchicine: Although the efficacy of colchicine is reported 
as poor and not recommended,1 recently, a prospective se-
ries of 20 HS patients (10 women and 10 men) treated with 
minocycline (100 mg/day) in combination with colchicine (0.5 
mg twice daily) for 6 months followed by a maintenance regi-
men of 0.5 mg colchicine twice daily for 3 months, showed a 
significant improvement as reflected in Hurley scoring system, 
Dermatology Life Quality Index questionnaire and physician’s 
global assessment scale (patients achieved substantial impro-
vement or complete remission).119
9.4 - Surgical Therapy 
Since most common non-surgical methods seldom re-
sult in a long-lasting cure, surgical treatment seems to be 
a quite common and accepted therapeutic modality.1 As 
surgical wounds heal best if inflammation is reduced befo-
rehand, antibiotics, especially those with anti-inflammatory 
properties, can be supplemented with short courses of pred-
nisone, cyclosporine, or biologic agents to reduce tissue in-
flammation in patients with severe disease.120 Recently, the 
role of noninvasive imaging techniques, as ultrasound and 
MRI, has been highlighted to guide surgeons in the complete 
removal of chronic HS lesions.11
Local destruction of individual small lesions may be at-
tempted. In fact repeated electrocauterization and curetta-
ge of the draining sinuses may be curative.1 Deroofing, in 
which the roof of a sinus tract is surgically removed and the 
floor of the lesion is left exposed to heal by second intention, 
has emerged as one of the most effective methods for HS 
treatment, with 83% of 73 patients showing no recurrence 
after a median follow-up of 34 months.121 Recently, Blok et 
al,122 described the promising skin-tissue-sparing excision 
with electrosurgical peeling (STEEP) technique for Hurley 
stage II–III disease,  performed under general anesthesia. 
In contrast to wide excisions that generally reach the deep 
subcutaneous fat, in STEEP the fat is maximally spared by 
performing successive tangential excisions of lesional tissue 
until reaching the epithelialized bottom of the sinus tracts. In 
addition, fibrotic tissue is completely removed in the same 
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manner. The healthy tissue at surgical margins is injected 
with triamcinolone acetonide 10-20 mg and bupivacai-
ne 0.5% (10 mL) to prevent hypergranulation and surgical 
wounds are left open to heal by secondary intention. This 
tissue-sparing technique results in low recurrence rates, high 
patient satisfaction with relatively short healing times and fa-
vorable cosmetic outcomes without contractures.122
Patients with chronic and extensive Hurley stage III disea-
se, if not amenable to deroofing, may be managed by wide 
excision of the entire affected area.120 After extensive tissue 
removal, the different options regarding closure will influen-
ce both the esthetic outcome and recurrence rate. Even large 
surgical defects may be allowed to heal by secondary inten-
tion, without contractures or reduced range of motion, with 
success rates as high as 89% - 72% at 1 year.1,120,123 Ano-
ther systematic review found 15% recurrence rate for prima-
ry closure, 8% for flaps, and 6% for grafts, after wide local 
excision.124
Pagliarello et al125 recently described a new technique, 
cryoinsufflation, a modified spray cryotherapy performed by 
injecting liquid nitrogen through a needle directly into HS 
tracts with good results.
9.5 - Lasers and Lights
Various laser and light treatments have been suggested 
in HS management.
CO2 laser ablation is an efficacious treatment with 
recurrence rate varying from 2 of 185 sites to 2 of 9 pa-
tients.126,127
Long-pulsed neodymium: yttrium-aluminum-garnet laser 
(Nd:YAG) designed for hair removal, has been tried in the 
treatment of HS lesions and background skin, based on the 
assumption that HS starts in the hair follicle.1 Reported impro-
vement rates range from 31.6% to 72.7%.128,129
Intense pulse light (IPL) used in a prospective trial of 18 
patients, showed a 55% reduction of the Sartorius score 
compared to 10% on the untreated side.130
Photodynamic therapy (PDT), reported in more than 20 
HS patients,1 has been described to have good to mediocre 
efficacy.131-134
In a retrospective trial with 13 patients bath psoralen 
plus ultraviolet A (PUVA) twice weekly, 5 patients had clea-
rance or near clearance of their lesions, 4 had moderate 
clearance, and 4 had minimal to no response.135
9.6 - Radiotherapy
Several series of patients have been treated with radio-
therapy with moderate results. Considering the spontaneous 
high risk of cancer in HS patients, this potentially carcinoge-
nic treatment should be considered with caution.136
9.7 - Pain management
The management of pain in patients with HS is complex 
and controlled trials are lacking. A multidisciplinary approa-
ch that features collaboration with a pain specialist is vital to 
achieve optimal care.137 Chronic pain management in pa-
tients with HS should follow the World Health Organization 
pain ladder (Table 7).1,137 Oral paracetamol and nonsteroi-
dal anti-inflammatory drugs are considered first-line agents, 
but if insufficient, oral opiates may be selected.137 Pregaba-
lin, gabapentin, tricyclic antidepressants and selective sero-
tonin reuptake inhibitors can offer long-term pain control.137
10. PROGNOSIS
There is no definitive consensus but HS severity seems 
greater among males.22 and involved areas also differ be-
tween genders, with the groin and submammary regions 
most commonly affected in women while the buttocks and 
perianal skin are the most affected areas in men.22
Chronicity is the rule in HS. In a questionnaire survey 
the mean duration of the active disease was 18.8 years.138 
However, disease tends to become less active among fema-
les in their 50s and is usually in complete remission after 
menopause. In males, HS may continue to be active in old 
age.136
As a chronic inflammatory dermatosis, HS is associated 
with a variety of concomitant and secondary diseases, name-
ly metabolic syndrome, several inflammatory and rheuma-
tologic disorders, depression, increased risk of malignancy 
and other complications.1 Recently, Egeberg et al,139 repor-
ted a study comprising 5964 HS patients without CV history 
(from the national register of Danish patients) matched to 
29,404 controls from the general Danish population with 
no CV background. Compared with the general population 
the risk of myocardial infarction (MI), ischemic stroke, CV-
-associated death and all-cause mortality was significantly 
increased in HS patients after adjustment for confounding 
factors and the risk of MI, ischemic stroke, and all-cause 
mortality was similar to that of patients with severe psoriasis, 
however, the risk of CV associated death was significantly 
higher in HS patients with HS than in psoriatic patients.139 
These novel findings suggest that HS is an independent risk 
factor for adverse CV outcomes.139
CONCLUSION
HS is a chronic and recurrent skin disease with significant 
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Table 7 - World Health Organization pain ladder*.
Step 1 Mid pain Non opiod + Optional adjuvant If pain persists or increases go to step 2.
Step 2 Moderate pain Weak opioid + Non opiod + Optional adjuvant If pain persists or increases, go to step 3.
Step 3 Severe pain Strong opioid + Non opiod + Optional adjuvant Freedom from pain.
*Adapted from Stjernsward J.140
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associated psychosocial morbidity. Reflecting the lack of an 
established pathogenic pathway, treatments for HS remain 
suboptimal. A growing body of research and evidence, 
however, is paving the way for better management of pa-
tients with this difficult condition. Often HS management re-
quires a multidisciplinary team and the team leader should 
be a dermatologist.
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1.  Relativamente à hidradenite supurativa (HS) 
assinale a afirmação falsa:
a) É uma dermatose inflamatória crónica do folículo 
piloso, sendo a inflamação das glândulas sebá-
ceas a este associadas, o primeiro passo da sua 
etiopatogenia
b)  Os critérios de diagnóstico estão bem estabeleci-
dos
c)  A etiologia é provavelmente multifatorial, envol-
vendo fatores genéticos, tabagismo, stress me-
cânico, obesidade, resposta aberrante imune e 
anormalidades hormonais
d)  A abordagem da HS requer uma equipa multidis-
ciplinar
2. Relativamente à hidradenite supurativa (HS) 
assinale a afirmação verdadeira:
a) Os mecanismos etiopatogenicos estão bem esta-
belecidos
b)  Apesar da maioria dos doentes terem excesso de 
peso, a obesidade não parece desempenhar um 
papel importante na etiopatogenia da HS 
c)  O tabagismo parece desempenhar um papel pro-
tetor
d)  A via IL-1b-IL-23 / TH17 / IL-17 foi recentemente 
implicada na etiopatogenia da HS
3. Relativamente ao tratamento da hidradenite 
supurativa (HS) assinale a afirmação verda-
deira:
a) O tratamento tópico nunca deve ser utilizado iso-
ladamente na abordagem aos doentes com HS 
b)  A administração de isotretinoína está associada a 
uma melhoria em cerca de 40% dos doentes com 
HS, sendo assim recomendada para doentes com 
HS moderada a grave.
c) Os fármacos mais prescritos no tratamento dos 
doentes com HS são os do grupo dos retinóides
d) A abordagem da HS varia amplamente depen-
dendo da gravidade da doença, sendo a maioria 
dos R: d
4. Relativamente à hidradenite supurativa (HS) 
assinale a afirmação verdadeira:
a) As áreas preferencialmente afetadas tendem a ser 
as mesmas em homens e mulheres
b) A doença tende a ficar menos ativa após a quinta 
década quer nos homens quer nas mulheres
c) Recentemente a HS foi associada a um risco signifi-
cativamente aumentado de eventos cardiovascula-
res adversos e de mortalidade por todas as causas
d) Apesar dos doentes com HS terem um risco car-
diovascular aumentado este parece ser significa-
tivamente menor do que aquele observados nos 
doentes com psoríase.
VErifiquE o quE aprENdEu
Chave: 1.a); 2.d); 3.d); 4.c)
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